Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Uncovering a Dual Th17/Type 2 Transcriptomic Endotype in Psoriasis.

Journal of the American Academy of Dermatology·2026

Same author

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

The Journal of dermatology·2026

Same author

Impact of Biologic Treatment Duration on Drug-Free Remission in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study.

Dermatology and therapy·2026

Same author

Dupilumab Treatment Provides Multidimensional Benefits in Patients with Prurigo Nodularis.

Dermatology and therapy·2026

Same author

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer's Disease?

Dermatology and therapy·2026

Same author

Psoriasis and Comorbid Moyamoya Angiopathy: Report of Three Chinese Patients and Review of the Literature.

The Journal of dermatology·2026

Same journal

Clinical response and time to improvement with 308-nm excimer laser therapy in scarring alopecia: a retrospective cohort study.

The Journal of dermatological treatment·2026

Same journal

Stapokibart provides significant improvements in signs and symptoms of atopic dermatitis irrespective of prior systemic treatment: a post-hoc analysis of a phase 3 trial.

The Journal of dermatological treatment·2026

Same journal

Active surveillance for basal cell carcinoma: experiences of patients and proxies.

The Journal of dermatological treatment·2026

Same journal

Severe cutaneous adverse reactions associated with systemic antibiotics in acne vulgaris: a systematic review.

The Journal of dermatological treatment·2026

Same journal

Intralesional human papillomavirus vaccination for cutaneous verrucae: a systematic review and meta-analysis of therapeutic efficacy.

The Journal of dermatological treatment·2026

Same journal

JAK inhibitor-associated acne: a mechanistic paradox with important clinical implications.

The Journal of dermatological treatment·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 24, 2026

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Intralesional therapy for psoriasis.

Ting-Shun Wang¹, Tsen-Fang Tsai

¹Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan, Republic of China.

The Journal of Dermatological Treatment

|March 7, 2012

Summary

This summary is machine-generated.

Intralesional therapy offers a targeted approach for localized psoriasis plaques resistant to systemic treatments. This review explores various intralesional agents, including corticosteroids and novel biologics, for effective psoriasis management.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Related Experiment Videos

Last Updated: May 24, 2026

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Area of Science:

Dermatology
Cutaneous Oncology
Immunology

Background:

Localized psoriasis plaques can be resistant to conventional systemic therapies.
Intralesional therapy is a recognized treatment modality for various skin conditions.
A gap exists in comprehensive reviews of intralesional treatments specifically for psoriasis.

Purpose of the Study:

To review the existing literature on the efficacy and application of intralesional therapies for psoriasis.
To consolidate information on a wide range of intralesional agents used or with potential for psoriasis treatment.

Main Methods:

Systematic literature search for studies on intralesional psoriasis treatment.
Categorization and discussion of reviewed agents based on their therapeutic class and mechanism of action.

Main Results:

Established intralesional agents include corticosteroids, methotrexate, and cyclosporine.
Emerging options encompass biologics, botulinum toxin type-A, and chemotherapy agents like 5-fluorouracil.
Potential future agents for intralesional use in psoriasis include bleomycin, rituximab, and bevacizumab.

Conclusions:

Intralesional therapy presents a valuable option for recalcitrant localized psoriasis.
A diverse array of agents, from traditional to novel, demonstrates potential for intralesional psoriasis treatment.
Further research is warranted to fully elucidate the role of specific intralesional agents in psoriasis management.